MX2021008152A - Metodos y materiales para aumentar los niveles del polipeptido del factor de transcripcion eb. - Google Patents
Metodos y materiales para aumentar los niveles del polipeptido del factor de transcripcion eb.Info
- Publication number
- MX2021008152A MX2021008152A MX2021008152A MX2021008152A MX2021008152A MX 2021008152 A MX2021008152 A MX 2021008152A MX 2021008152 A MX2021008152 A MX 2021008152A MX 2021008152 A MX2021008152 A MX 2021008152A MX 2021008152 A MX2021008152 A MX 2021008152A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- polypeptide levels
- methods
- nucleus
- materials
- Prior art date
Links
- 102100028502 Transcription factor EB Human genes 0.000 title abstract 8
- 229920001184 polypeptide Polymers 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 6
- 239000000463 material Substances 0.000 title abstract 2
- 101710162524 Transcription factor EB Proteins 0.000 title 1
- 101000837841 Homo sapiens Transcription factor EB Proteins 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788049P | 2019-01-03 | 2019-01-03 | |
| US201962879374P | 2019-07-26 | 2019-07-26 | |
| PCT/US2020/012268 WO2020142748A1 (en) | 2019-01-03 | 2020-01-03 | Methods and materials for increasing transcription factor eb polypeptide levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008152A true MX2021008152A (es) | 2021-10-13 |
Family
ID=71406977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008152A MX2021008152A (es) | 2019-01-03 | 2020-01-03 | Metodos y materiales para aumentar los niveles del polipeptido del factor de transcripcion eb. |
Country Status (12)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4178955A1 (en) | 2020-07-11 | 2023-05-17 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CZ309449B6 (cs) * | 2020-12-24 | 2023-01-25 | Ústav experimentální botaniky AV ČR, v. v. i. | Chinazolinové deriváty jako selektivní inhibitory cyklooxygenázy-1 |
| CN113248518B (zh) * | 2021-06-21 | 2022-03-25 | 山东大学 | 嘧啶哌嗪类衍生物及其制备方法与应用 |
| CN121941701A (zh) * | 2023-07-28 | 2026-04-28 | 特兰埃克斯公司 | 用于治疗溶酶体病症的突变tfeb |
| CN119818678A (zh) * | 2024-12-24 | 2025-04-15 | 广州医科大学附属妇女儿童医疗中心 | Tfeb在制备变应性鼻炎的药物中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| AU2001290912A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Pharmaceuticals, Inc. | Delivery of drug esters through an inhalation route |
| US20030158195A1 (en) * | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
| US7262200B2 (en) | 2002-10-25 | 2007-08-28 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| US7198926B2 (en) | 2003-05-08 | 2007-04-03 | E. I. Du Pont De Nemours And Company | Preparation of (E)- and (Z)-2-methyl-2-butenoic acids |
| JP2006528694A (ja) | 2003-05-13 | 2006-12-21 | スミスクライン ビーチャム コーポレーション | ナフチリジンインテグラーゼインヒビター |
| WO2008157500A1 (en) | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| WO2009062118A2 (en) * | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| US8604049B2 (en) * | 2008-08-05 | 2013-12-10 | Boehringer Ingelheim International Gmbh | 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments |
| JP2011529932A (ja) * | 2008-08-05 | 2011-12-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ナフチリジン及び医薬としてのその使用 |
| GB201007203D0 (en) * | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| RU2015120217A (ru) | 2012-11-20 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Замещенные 1,6-нафтиридины |
| EP4026545A1 (en) | 2014-11-19 | 2022-07-13 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
| EP3538091A4 (en) * | 2016-11-08 | 2020-06-10 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF |
| WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| WO2018089493A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PYRROLE mTORC INHIBITORS AND USES THEREOF |
| WO2018191146A1 (en) * | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
-
2020
- 2020-01-03 SG SG11202105685TA patent/SG11202105685TA/en unknown
- 2020-01-03 EP EP20736104.9A patent/EP3906033A4/en active Pending
- 2020-01-03 JP JP2021538743A patent/JP7566753B2/ja active Active
- 2020-01-03 AU AU2020204717A patent/AU2020204717B2/en active Active
- 2020-01-03 CA CA3123902A patent/CA3123902A1/en active Pending
- 2020-01-03 CN CN202080007921.4A patent/CN113316453B/zh active Active
- 2020-01-03 MX MX2021008152A patent/MX2021008152A/es unknown
- 2020-01-03 WO PCT/US2020/012268 patent/WO2020142748A1/en not_active Ceased
- 2020-01-03 US US17/420,597 patent/US12286442B2/en active Active
- 2020-01-03 KR KR1020217022772A patent/KR102904932B1/ko active Active
- 2020-01-03 BR BR112021012950-2A patent/BR112021012950A2/pt unknown
-
2021
- 2021-06-27 IL IL284403A patent/IL284403A/en unknown
-
2025
- 2025-01-23 US US19/035,805 patent/US20250382309A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL284403A (en) | 2021-08-31 |
| CN113316453A (zh) | 2021-08-27 |
| JP2022516631A (ja) | 2022-03-01 |
| KR102904932B1 (ko) | 2025-12-26 |
| SG11202105685TA (en) | 2021-06-29 |
| JP7566753B2 (ja) | 2024-10-15 |
| EP3906033A1 (en) | 2021-11-10 |
| BR112021012950A2 (pt) | 2021-09-14 |
| KR20210111787A (ko) | 2021-09-13 |
| US20220112218A1 (en) | 2022-04-14 |
| US20250382309A1 (en) | 2025-12-18 |
| WO2020142748A1 (en) | 2020-07-09 |
| EP3906033A4 (en) | 2022-11-09 |
| CN113316453B (zh) | 2025-12-23 |
| US12286442B2 (en) | 2025-04-29 |
| AU2020204717B2 (en) | 2025-01-16 |
| CA3123902A1 (en) | 2020-07-09 |
| AU2020204717A1 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| BR112019013005A2 (pt) | espécie de metschnikowia isolada, método para produzir xilitol, xilitol bioderivado e composição | |
| WO2019014395A8 (en) | GENERATION OF WATER-SOLUBLE CANNABINOID COMPOUNDS IN PLANT CELL SUSPENSION YEAST AND CROPS AND MATERIAL COMPOSITIONS | |
| EP4287191A3 (en) | Hla-based methods and compositions and uses thereof | |
| MX2021011119A (es) | Nueva cepa de paenibacillus, compuestos antifungicos y metodos para su uso. | |
| NZ599174A (en) | Combinations comprising a fungicidal strain and an azolopyrimidin-7-ylamine | |
| WO2018064594A3 (en) | Hla class i-deficient nk-92 cells with decreased immunogenicity | |
| EP4541385A3 (en) | Adipose tissue products and methods of production | |
| MX2021010918A (es) | Composiciones y metodos para tratar la mucopolisacaridosis tipo i. | |
| EP4600650A3 (en) | Improved methods and compositions for synthetic biomarkers | |
| MX2020001666A (es) | Biopesticidas. | |
| MX2025008949A (es) | Arni variante | |
| MX2021006674A (es) | Composiciones para estabilizar bacterias y usos de las mismas. | |
| MY185961A (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| MY191497A (en) | Curable composition comprising an ethylene polymer, a monoperoxycarbonate and a t-alkyl hydroperoxide | |
| BR112018010499A8 (pt) | método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, população de células in vitro, método para produzir uma população de células, e população de células | |
| IL292004B2 (en) | Composition for reprogramming cells into plasmacytoid dendritic cells or interferon type i-producing cells, methods and uses thereof | |
| AU2017248848A1 (en) | Enhanced gene delivery methods | |
| CL2023003260A1 (es) | Composiciones y métodos para el tratamiento de la hipoacusia neurosensorial mediante sistemas de vector dual de estereocilina. | |
| EP4549947A3 (en) | Reducing the risk of major adverse cardiac events | |
| GB2556595A (en) | Solid hydrogen storage system | |
| ZA202404295B (en) | Anti-mutant calreticulin (calr) antibodies and uses thereof | |
| WO2021041716A3 (en) | Therapeutic editing to treat cardiomyopathy | |
| WO2019070435A8 (en) | Methods for selectively expanding cells expressing a tcr with a murine constant region | |
| WO2020214100A3 (en) | Composition |